Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00477802 · ClinicalTrials.gov registry record · Phase 4
Botulinum Toxin Type A (Botox) in the Management of Levodopa-Induced Peak-Dose Dyskinesias in Parkinson's Disease
A Phase 4 study, sponsored by University of Cincinnati.
- Terminated
- Registry status
- Phase 4
- Development phase
- 8
- Enrollment target
NCT00477802 is a Phase 4 study that was terminated before completion, run by University of Cincinnati. The registered enrollment target is 8 participants.
The verdict
NCT00477802, a Phase 4 study, was terminated before completion, sponsored by University of Cincinnati.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 8 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine whether intramuscular injections of botulinum toxin type A (Botox®) in selected cervical muscles at antidystonic dosages can reduce levodopa-induced peak-dose dyskinesias (LID) in the cervical region in adult patients with idiopathic Parkinson's disease. It is hypothesized that the intramuscular injection of antidystonic doses of botulinum toxin into cervical muscles will decrease the duration and severity of LID in the cervical region in patients with Parkinson's disease (PD).
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Botulinum Toxin Type A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2007-05 |
| Est. Completion | 2008-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00477802
The ClinicalTrials.gov registry entry for NCT00477802 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Cincinnati, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00477802 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00477802 about?
NCT00477802 is a clinical study titled "Botulinum Toxin Type A (Botox) in the Management of Levodopa-Induced Peak-Dose Dyskinesias in Parkinson's Disease". The primary objective of this study is to determine whether intramuscular injections of botulinum toxin type A (Botox®) in selected cervical muscles at antidystonic dosages can reduce levodopa-induced peak-dose dyskinesias (LID) in the cervical region in adult patients with idiopathic Parkinson's di...
What is the current status of trial NCT00477802?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 8 participants. The study started on 2007-05. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00477802?
The interventions under investigation include: Placebo (BIOLOGICAL), Botulinum Toxin Type A (BIOLOGICAL).
Who is sponsoring clinical trial NCT00477802?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.